Traitomic raises €20m to accelerate market-ready trait development

Image via Traitomic

Traitomic, a Danish biotechnology company developing market-ready, non-GE/non-GM traits in plants and microorganisms, has raised €20 million in a Series A round led by Sofinnova Partners.

The investor consortium includes the Export and Investment Fund of Denmark (EIFO), Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures.

The round marks Traitomic’s first external investment since its spin-out from Carlsberg and follows the growth of its customer base across multiple industries. The funding will support international expansion and continued development of the company’s scientific and commercial capabilities.

Continuous improvement in biological performance addresses challenges in food security, resource efficiency, and sustainability. Despite its importance, translating a biological need into a commercially relevant trait can be slow, fragmented, and difficult to scale. Traitomic bridges that gap by developing market-ready traits and supporting customers from initial commercial challenges through deployment.

Traitomic’s proprietary FIND-IT platform identifies specific genetic variants in conventionally bred populations without gene editing, enabling rapid trait development while maintaining broad regulatory and commercial applicability. The platform can also be applied across both plant and microbial systems.

So far, Traitomic has delivered 116 traits to 47 customers across 32 organisms spanning plant breeding and seed; food supply chain and precision nutrition; and biosolutions and industrial biotech. The projects have improved crop robustness, developed differentiated food products with enhanced flavour, nutrition or shelf life, and optimised enzymes and strains used in industrial biotechnology. This range of applications reflects customer demand across multiple industries and highlights the opportunity to expand trait development across the broader bioeconomy.

The funding will support Traitomic’s international expansion and help the company capitalise on this opportunity across food, agriculture, and biosolutions markets.

Traitomic will also continue to expand its integrated offering, enabling closer collaboration with customers from initial biological or commercial challenges through delivery of market-ready traits.

Gustav Hambraeus, CEO and co-founder, Traitomic said, “This investment marks the beginning of Traitomic’s next chapter. Over the past years, we have demonstrated that customers across the food value chain are looking for faster routes from biological insight to commercial impact. With the support of our new investors, we can now expand internationally, deepen our collaboration with customers and bring our integrated approach to trait development to many more innovation challenges.”

Michael Krel, partner, Sofinnova Partners, said, “Traitomic has demonstrated something that is rare in biological innovation: the ability to develop commercially relevant traits across a broad range of organisms and applications. Combined with the company’s strong customer traction and proven track record, this creates a compelling foundation for future growth. We believe Traitomic is well positioned to become a leading partner for trait development across agriculture, food and industrial biotechnology, and we look forward to supporting the team with both capital and experience as they enter their next phase of international expansion.”

Anders Røed, executive vice president, Group Strategy and Commercial, Carlsberg, said, “Traitomic is an excellent example of how fundamental research can create value far beyond its original field of application. FIND-IT was developed at Carlsberg Research Laboratory to improve barley, and it is now enabling advances in agriculture, food production and industrial biotechnology. I am proud of what the team has achieved and excited to continue supporting the company as it enters this next phase of international growth.”

Share This Article
Leave a Comment

Subscribe to our Newsletter

© 2026 Setform Limited.